TransEnterix Announces Maastricht University Medical Center+ in the Netherlands to Initiate Program with the Senhance Surgica...
July 27 2020 - 6:50AM
Business Wire
TransEnterix, Inc. (NYSE American:TRXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to improve minimally invasive surgery, today announced
that Maastricht University Medical Center+ (MUMC+) has entered into
an agreement to lease and utilize a Senhance® Surgical System,
which would be the first hospital to acquire a Senhance to be
utilized in pediatric minimally invasive surgery.
“This new program is a major milestone for the growth of
Senhance,” said Anthony Fernando, president and chief executive
officer at TransEnterix. “Maastricht UMC+ will be the first
hospital utilizing Senhance in a comprehensive multi-specialty
program led by pediatric surgery and the Woman-Mother-Child Center.
We are pleased to partner with a leading medical center like
Maastricht UMC+, and this program highlights the continued momentum
we are seeing in areas such as the Netherlands and Germany.”
The Senhance System is the first and only digital laparoscopic
surgical platform designed to maintain laparoscopic MIS standards
while providing digital benefits such as haptic feedback, robotic
precision, comfortable ergonomics, advanced instrumentation
including, 3 mm mini-laparoscopic instruments, eye sensing camera
control and reusable standard instruments to help maintain
per-procedure costs similar to traditional laparoscopy. In February
2020, TransEnterix received CE Mark approval for expanded
indication of use to include pediatric patients.”
“The Senhance System is a unique new offering in utilizing
digital assistance in treating pediatric patients,” said Prof. Dr.
Wim van Gemert, chairman of the department of pediatric surgery,
Maastricht University Medical Center+ in the Netherlands. “The
combination of haptic feedback, minimization of forces generated at
the abdominal wall, digital precision and small, 3mm robotic
instruments are unmatched as important tools for pediatric surgeons
performing complex procedures.”
Senhance European Indication for Use
The Senhance® Surgical System has received a CE Mark according
to the Medical Device Directive and is intended to be used for
laparoscopic surgery in the abdomen, pelvis and limited uses in the
thoracic cavity excluding the heart and greater vessels. The
Senhance System is indicated for adult and pediatric use in CE
marked territories.
About TransEnterix
At TransEnterix, Inc., we are digitizing the interface between
the surgeon and the patient to improve minimally invasive surgery
(MIS) through a new category of care called Digital Laparoscopy.
Digitizing the interface enables the use of advanced capabilities
like augmented intelligence, connectivity and robotics in
laparoscopy, and allows us to address the current clinical,
cognitive and economic shortcomings in surgery. The Senhance®️
Surgical System brings the benefits of Digital Laparoscopy to
patients around the world while staying true to the principles of
value-based healthcare. Learn more about Digital Laparoscopy with
the Senhance Surgical System here: https://Senhance.com/. Now
available for sale in the US, the EU, Japan, and select other
countries. For a complete list of indications for use, please
visit: https://www.transenterix.com/indications-for-use/.
About Maastricht UMC+
Maastricht University Medical Center+ is known both nationally
and internationally for its focus on prevention and taking an
integrated approach to health care: from prevention, promotion of
good health, and basic care, to top-level clinical diagnostics and
treatment. Patient safety is our top priority in all of our
endeavours. Maastricht UMC+ has 715 beds and approximately 7,000
employees and 4,000 students. Maastricht UMC+ is part of The
Netherlands Federation of University Medical Centres.
Forward-Looking Statements
This press release includes statements relating to the Senhance
System and the Maastricht University Medical Center+ initiating a
program with the Senhance System. These statements and other
statements regarding our future plans and goals constitute "forward
looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and are intended to qualify for the safe harbor from
liability established by the Private Securities Litigation Reform
Act of 1995. Such statements are subject to risks and uncertainties
that are often difficult to predict, are beyond our control and
which may cause results to differ materially from expectations and
include whether the Senhance System at Maastricht UMC+ will
continue the momentum TransEnterix is seeing in areas such as the
Netherlands and Germany. For a discussion of the risks and
uncertainties associated with TransEnterix's business, please
review our filings with the Securities and Exchange Commission
(SEC), including our Annual Report on Form 10-K for the year ended
December 31, 2019, filed with the SEC on March 16, 2020 and our
other filings we make with the SEC. You are cautioned not to place
undue reliance on these forward looking statements, which are based
on our expectations as of the date of this press release and speak
only as of the origination date of this press release. We undertake
no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200727005147/en/
For TransEnterix, Inc. Investor Contact: Mark Klausner, +1
443-213-0501 invest@transenterix.com
or
Media Contact: Terri Clevenger, +1 203-682-8297
terri.clevenger@icrinc.com
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Sep 2023 to Sep 2024